Loading....

Research led by Michigan Medicine’s Scleroderma Program and published in Arthritis & Rheumatology found that tocilizumab, a FDA-approved anti-inflammatory drug used to combat rheumatoid arthritis, can prevent lung disease in patients with systemic sclerosis if detected early enough in the disease course.

Leave a Reply